Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05577000
What this trial is testing

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Thomas Martin, MD 5
Testing effectiveness (Phase 2)Ended earlyNCT00719901
What this trial is testing

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Ended earlyNCT02254551
What this trial is testing

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 7
Not applicableNot Yet RecruitingNCT06825845
What this trial is testing

Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

Who this might be right for
Relapsed or Refractory Multiple Myeloma
CARsgen Therapeutics Co., Ltd. 1,500
Testing effectiveness (Phase 2)WithdrawnNCT03856112
What this trial is testing

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myelomat(11;14) Negative
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00448201
What this trial is testing

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 71
Testing effectiveness (Phase 2)Ended earlyNCT04735575
What this trial is testing

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd. 40
Early research (Phase 1)Study completedNCT04671251
What this trial is testing

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Avalo Therapeutics, Inc. 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT05704049
What this trial is testing

Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Sanofi 118
Testing effectiveness (Phase 2)UnknownNCT00003885
What this trial is testing

Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Our Lady of Mercy Medical Center 60
Testing effectiveness (Phase 2)Study completedNCT02509052
What this trial is testing

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center 12
Testing effectiveness (Phase 2)WithdrawnNCT04024384
What this trial is testing

Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial

Who this might be right for
Multiple Myeloma
Assistance Publique - Hôpitaux de Paris
Early research (Phase 1)Looking for participantsNCT07802717
What this trial is testing

Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma RefractoryMultiple Myeloma in Relapse
Vyriad, Inc. 40
Early research (Phase 1)Study completedNCT03464916
What this trial is testing

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03933735
What this trial is testing

TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
AbbVie 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT04586426
What this trial is testing

The Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 228
Testing effectiveness (Phase 2)Study completedNCT00482378
What this trial is testing

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Who this might be right for
Multiple Myeloma and Plasma Cell NeoplasmPain
Mayo Clinic 39
Not applicableStudy completedNCT00716911
What this trial is testing

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
City of Hope Medical Center 100
Large-scale testing (Phase 3)Study completedNCT03357952
What this trial is testing

JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 10
Not applicableStudy completedNCT04035226
What this trial is testing

Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Who this might be right for
Multiple Myeloma
Janssen-Cilag Ltd. 254
Next Page